Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Filings indexed 767 across all filing types
Latest filing 2022-11-09 Interim / Quarterly Rep…
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2022
2022-11-09 English
8-K
Regulatory Filings
2022-11-09 English
Regulatory Filings 2022
Regulatory Filings
2022-11-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-11-03 English
Participation in Upcoming Investor Conferences
Regulatory Filings Classification · 1% confidence The document is a short announcement (under 5,000 characters) regarding management's participation in upcoming investor conferences. It does not contain financial results, proxy materials, or specific regulatory filings, but rather serves as a general corporate announcement distributed via the RNS Reach service. Since it does not fit into specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', it is classified as a general regulatory filing/announcement.
2022-11-02 English
Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an RNS announcement from MaxCyte, Inc. regarding the issuance of new common stock following the exercise of share options and the subsequent update to the total voting rights (denominator for shareholder notifications). This falls under the category of share capital changes and issuance of new shares.
2022-11-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.